Performance of Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience
Zurich Open Repository and Archive (University of Zurich) · 02.02.2026
DOI: 10.5167/uzh-284363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 02.02.2026. Verfasst von Rowe und 41 weiteren Autor:innen.
Abstract (Originalsprache)
Purpose
Anatomic imaging and biopsy have limitations in the risk stratification of indeterminate renal masses. Molecular imaging offers opportunities to improve noninvasive risk stratification. Tc-sestamibi is a mitochondrial imaging agent that has shown increased uptake in benign/indolent renal tumors and a lack of uptake in aggressive renal cell carcinomas (RCCs). Materials and methods: We evaluated the accuracy of Tc-sestamibi single-photon emission CT (SPECT/CT) imaging to characterize histologically diagnosed renal masses using 2 cohorts of patients; one from a prospective scan-and-resect clinical trial and a second from routine clinical care. The rate of renal mass positivity (ie, "hot tumors") on Tc-sestamibi SPECT/CT was stratified by histology. Diagnostic performance to identify histologic groupings of interest was measured by sensitivity and specificity.
Results
Three hundred forty-four patients with 361 tumors (124 trial, 237 clinical) were included. Most clear cell RCC (97%) and papillary or clear cell papillary RCC (80%-84%) were cold while chromophobe RCCs were equally likely to be hot or cold (52% vs 48%). Surgically resected oncocytomas tended to be hot (69%), with even higher positivity for biopsy with oncocytic neoplasms in the clinical cohort (87%). Limitations included the heterogeneous nature of the cohort and the use of biopsy for histologic diagnosis in the clinical cohort.
Conclusions
Tc-sestamibi SPECT/CT is a novel method to effectively risk-stratify indeterminate renal masses. As with any nonsurgical method for renal mass characterization, there are potential false positives and false negatives, and those should be weighed carefully in shared decision-making with the patient to guide further evaluation and management.
Schlagwörter
Zitieren
APA
Rowe, P, S., Murtazaliev, Salikh, Amindarolzarbi, Alireza, Sheikhbahaei, Sara, Meyer, R, A., Javadi, S, M., Wood, McKenna, Kaufmann, Basil, Goel, Reema, Viglianti, …, & A, M. (2026). Performance of Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-284363
Vancouver
Rowe, P S, Murtazaliev, Salikh, Amindarolzarbi, Alireza, et al. Performance of Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience. Zurich Open Repository and Archive (University of Zurich). 2026. doi:10.5167/uzh-284363
BibTeX
@article{Rowe2026,
author = {Rowe and P, Steven and Murtazaliev and Salikh and Amindarolzarbi and Alireza and Sheikhbahaei and Sara and Meyer and R, Alexa and Javadi and S, Mehrbod and Wood and McKenna and Kaufmann and Basil and Goel and Reema and Viglianti and L, Benjamin and Pavlovich and P, Christian and Singla and Nirmish and Pierorazio and M, Philip and Baras and S, Alex and Epstein and I, Jonathan and Baraban and Ezra and Allaf and E, Mohamad and Solnes and B, Lilja and Oldan and D, Jorge and Patel and D, Hiten and Gorin and A, Michael},
title = {Performance of Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience},
journal = {Zurich Open Repository and Archive (University of Zurich)},
year = {2026},
doi = {10.5167/uzh-284363}
}
EUVIMED